布比卡因脂质体的药理特性与研究进展

doi:10.11958/20260369

天津医药 ›› 2026, Vol. 54 ›› Issue (8): 881-885.doi: 10.11958/20260369

布比卡因脂质体的药理特性与研究进展

鲁富泰(), 杨涛, 王婷, 王蕾^△()

天津市人民医院，南开大学第一附属医院麻醉科（邮编300121）

收稿日期:2026-02-02 修回日期:2026-05-01 出版日期:2026-08-15 发布日期:2026-08-07
通讯作者: △E-mail：tumcmzk@163.com
作者简介:鲁富泰（1982），男，主治医师，主要从事神经阻滞方面研究。E-mail：lft2005@163.com
基金资助:
国家自然科学基金资助项目(82102248)

The pharmacological properties and research status of liposomal bupivacaine

LU Futai(), YANG Tao, WANG Ting, WANG Lei^△()

Department of Anesthesiology, Tianjin Union Medical Center, the First Affiliated Hospital of Nankai University, Tianjin 300121, China

Received:2026-02-02 Revised:2026-05-01 Published:2026-08-15 Online:2026-08-07
Contact: △E-mail: tumcmzk@163.com

鲁富泰, 杨涛, 王婷, 王蕾. 布比卡因脂质体的药理特性与研究进展[J]. 天津医药, 2026, 54(8): 881-885.

LU Futai, YANG Tao, WANG Ting, WANG Lei. The pharmacological properties and research status of liposomal bupivacaine[J]. Tianjin Medical Journal, 2026, 54(8): 881-885.

摘要/Abstract

摘要：

局部麻醉药在临床麻醉和疼痛管理中占据重要地位，然而传统局部麻醉药的作用时间有限，限制了其在术后镇痛领域的应用效果。布比卡因脂质体作为一种新型长效局部麻醉药，通过独特的DepoFoam技术显著延长了药物作用时间，为疼痛管理带来了新的解决方案。自2011年美国食品药品监督管理局首次批准其用于伤口浸润以控制术后疼痛以来，布比卡因脂质体在全球范围内逐渐受到关注，相关研究不断涌现。该文系统阐述布比卡因脂质体的药代动力学及药效学等药理特性，并全面梳理其在局部浸润麻醉、神经阻滞麻醉及特殊人群中的临床研究进展，旨在为临床合理规范使用布比卡因脂质体及优化围手术期镇痛方案提供循证依据。

关键词: 布比卡因, 脂质体, 镇痛, 麻醉, 局部, 药理学

Abstract:

Local anesthetics play a significant role in clinical anesthesia and pain management. However, the duration of action of traditional local anesthetics is limited, which restricts their application in the field of postoperative analgesia. Liposomal bupivacaine, as a novel long-acting local anesthetic, significantly prolongs the duration of drug action through its unique DepoFoam technology, offering a new solution for pain management. Since the U.S. Food and Drug Administration (FDA) first approved bupivacaine liposome for wound infiltration to control postoperative pain in 2011, it has gradually attracted global attention, and related studies have emerged continuously. This article will elaborate the pharmacological properties of liposomal bupivacaine including pharmacokinetics and pharmacodynamics, and comprehensively review its clinical research progress in local infiltration anesthesia, nerve block anesthesia and application in special populations, so as to provide evidence-based references for the rational and standardized clinical application of liposomal bupivacaine and the optimization of perioperative analgesia regimens.

Key words: bupivacaine, liposomes, analgesia, anesthesia, local, pharmacology

中图分类号:

R614.3

参考文献 32

[1]	刘子策, 安奕, 李丽霞, 等. 术后疼痛与术后谵妄的研究进展[J]. 临床麻醉学杂志, 2025, 41(9):974-977.
	Liu Z C, An Y, Li L X, et al. Research advances in postoperative pain and postoperative delirium[J]. Journal of Clinical Anesthesia, 2025, 41(9):974-977. doi:10.12089/jca.2025.09.013.
[2]	El-Boghdadly K, Levy N A, Fawcett W J, et al. Peri-operative pain management in adults:a multidisciplinary consensus statement from the Association of Anaesthetists and the British Pain Society[J]. Anaesthesia, 2024, 79(11):1220-1236. doi:10.1111/anae.16391.
[3]	Zadrazil M, Marhofer P, Opfermann P, et al. Liposomal bupivacaine for peripheral nerve blockade:a randomized,controlled,crossover,triple-blinded pharmacodynamic study in volunteers[J]. Anesthesiology, 2024, 141(1):24-31. doi:10.1097/ALN.0000000000004988.
[4]	Delaney J B, Landry L P, Coggins N C, et al. The emerging role of liposomal bupivacaine in erector spinae plane blocks for post-operative pain management in spine surgeries:a narrative review[J]. Clin Pharmacol, 2025, 17:339-346. doi:10.2147/CPAA.S575987.
[5]	Chen D X, Chen X M, Chen S M, et al. Real-world pharmacovigilance analysis of adverse events associated with liposomal bupivacaine and bupivacaine[J]. J Pain Res, 2025, 18:1805-1816. doi:10.2147/JPR.S519504.
[6]	沈筱苒, 齐择优, 张官正, 等. 布比卡因脂质体用于心脏手术后镇痛的研究进展[J]. 临床麻醉学杂志, 2026, 42(1):71-75.
	Shen X R, Qi Z Y, Zhang G Z, et al. Advances in use of liposomal bupivacaine for postoperative analgesia after cardiac surgery[J]. Journal of Clinical Anesthesia, 2026, 42(1):71-75. doi:10.12089/jca.2026.01.014.
[7]	Sessler D I, Bao X, Leiman D, et al. A phase Ⅰ study of the pharmacokinetics,pharmacodynamics,and safety of liposomal bupivacaine for sciatic nerve block in the popliteal fossa for bunionectomy[J]. J Clin Pharmacol, 2025, 65(4):441-451. doi:10.1002/jcph.6159.
[8]	彭浩彬, 温嘉筠, 吴先平, 等. 布比卡因脂质体的临床应用与争议性[J]. 中国医药指南, 2024, 22(21):54-57.
	Peng H B, Wen J Y, Wu X P, et al. Clinical application and controversy of bupivacaine liposomes[J]. Guide of China Medicine, 2024, 22(21):54-57. doi:10.15912/j.issn.1671-8194.2024.21.015.
[9]	Sun H, Lu Y, Wang Y. Research progress of liposomal bupivacaine and its value in perioperative pain management[J]. JPRAS Open, 2025, 45:311-316. doi:10.1016/j.jpra.2025.06.022.
[10]	Huang H, Wei S, Lan Y, et al. Liposomal bupivacaine versus ropivacaine perianal infiltration for postoperative analgesia of haemorrhoidectomy:a multicentre,randomised controlled trial[J]. BMJ Open, 2025, 15(10):e098484. doi:10.1136/bmjopen-2024-098484.
[11]	Mauras J, McMahon M, Petrie J, et al. Reduction in opioid requirements following changes to regional anesthesia for patients undergoing total knee arthroplasty[J]. Ochsner J, 2025, 25(2):99-106. doi:10.31486/toj.24.0137.
[12]	郑善斌, 胡虹钰, 夏天卫, 等. 布比卡因脂质体局部浸润麻醉在膝关节单髁置换术后镇痛疗效的前瞻性随机对照研究[J]. 中国修复重建外科杂志, 2024, 38(12):1458-1465.
	Zheng S B, Hu H Y, Xia T W, et al. Observation of analgesic efficacy of liposomal bupivacaine for local infiltration anesthesia in unicompartmental knee arthroplasty:a prospective randomized controlled study[J]. Chinese Journal of Reparative and Reconstructive Surgery, 2024, 38(12):1458-1465. doi:10.7507/1002-1892.202408085.
[13]	Bowen J, Rainey J P, Linthicum J, et al. Liposomal bupivacaine versus standard periarticular injections in total hip and knee arthroplasty:a prospective, randomized non-inferiority trial[J]. SICOT J, 2025, 11:17. doi:10.1051/sicotj/2025012.
[14]	Lee K K, Jeong W, Chae M. Hydrogel drug delivery systems and liposomal bupivacaine:innovations and future perspectives in pain management[J]. J Clin Med, 2025, 14(21):7824. doi:10.3390/jcm14217824.
[15]	Viscusi E R, Candiotti K A, Onel E, et al. The pharmacokinetics and pharmacodynamics of liposome bupivacaine administered via a single epidural injection to healthy volunteers[J]. Reg Anesth Pain Med, 2012, 37(6):616-622. doi:10.1097/AAP.0b013e318269d29e.
[16]	Gasteiger L, Kirchmair L, Hoerner E, et al. Peripheral regional anesthesia using local anesthetics:old wine in new bottles?[J]. J Clin Med, 2023, 12(4):1541. doi:10.3390/jcm12041541.
[17]	Li M, Wang W, Yang Y, et al. Efficacy of bupivacaine liposome transversus abdominis plane block in enhancing postoperative recovery following laparoscopic colorectal cancer resection[J]. Langenbecks Arch Surg, 2025, 410(1):286. doi:10.1007/s00423-025-03752-2.
[18]	Dong L, Wang X, Fu L, et al. Efficacy and safety of bupivacaine liposomal in intercostal nerve block for postoperative pain management following uniportal thoracoscopy:a randomized trial[J]. Pain Res Manag, 2025, 2025:8816879. doi:10.1155/prm/8816879.
[19]	Wang C, Zheng B, Lin C, et al. Effects of liposomal bupivacaine for erector spinae plane block on perioperative immune function and analgesia in thoracoscopic lung cancer surgery[J]. Am J Cancer Res, 2025, 15(8):3728-3739. doi:10.62347/SQHE7607.
[20]	Gong H, Wang Z, Kou G, et al. Liposomal bupivacaine for quadratus lumborum block at the lateral supra-arcuate ligament in the analgesic effect after laparoscopic nephrectomy:a single-centre,triple-blind,randomized controlled trial[J]. J Pain Res, 2025, 18:4999-5009. doi:10.2147/JPR.S550175.
[21]	Rytel H, Rashid B, Kaczmarski P, et al. Quadratus lumborum block:the new gold standard in abdominal analgesia?[J]. Cureus, 2025, 17(7):e88051. doi:10.7759/cureus.88051.
[22]	Chen Z, Liu Z, Feng C, et al. Dexmedetomidine as an adjuvant in peripheral nerve block[J]. Drug Des Devel Ther, 2023, 17:1463-1484. doi:10.2147/DDDT.S405294.
[23]	Shing C H, Wang F, Lam P M, et al. Addition of liposomal bupivacaine in brachial plexus blocks:a systematic review and meta-analysis of randomized controlled trials[J]. Reg Anesth Pain Med, 2026, 51(6):611-620. doi:10.1136/rapm-2025-106583.
[24]	Quaye A, McAllister B, Garcia J R, et al. A prospective,randomized trial of liposomal bupivacaine compared to conventional bupivacaine on pain control and postoperative opioid use in adults receiving adductor canal blocks for total knee arthroplasty[J]. Arthroplasty, 2024, 6(1):6. doi:10.1186/s42836-023-00226-y.
[25]	Schwartz G, Gadsden J C, Gonzales J, et al. A phase 3 active-controlled trial of liposomal bupivacaine via sciatic nerve block in the popliteal fossa after bunionectomy[J]. J Clin Anesth, 2024, 94:111402. doi:10.1016/j.jclinane.2024.111402.
[26]	Ma W, Long Y, Ye S, et al. Epidural analgesia combined with transversus abdominis plane block with liposomal bupivacaine reduces pain after caesarean delivery:a double-blind,randomised controlled trial[J]. Front Med (Lausanne), 2025, 12:1653815. doi:10.3389/fmed.2025.1653815.
[27]	Mustafa H J, Wong H L, Al-Kofahi M, et al. Bupivacaine pharmacokinetics and breast milk excretion of liposomal bupivacaine administered after cesarean birth[J]. Obstet Gynecol, 2020, 136(1):70-76. doi:10.1097/AOG.0000000000003886.
[28]	Ma W, Liu Y, Li Y, et al. Efficacy of bilateral quadratus lumborum block with liposomal bupivacaine for post-cesarean analgesia:a protocol for an open-label randomized controlled trial[J]. Front Med(Lausanne), 2025, 12:1654019. doi:10.3389/fmed.2025.1654019.
[29]	Le S, Lo C, Wong J Y, et al. Effectiveness of liposomal bupivacaine in adductor canal blocks for pediatric knee procedures:a case series[J]. J Clin Anesth, 2021, 75:110517. doi:10.1016/j.jclinane.2021.110517.
[30]	Walls H R, Thomas E S, Kain Z N, et al. Does liposomal bupivacaine injectable suspension peripheral nerve block further aid in decreasing at-home narcotic utilization in children and adolescents after anterior cruciate ligament reconstruction[J]. J Pediatr Orthop, 2023, 43(8):511-515. doi:10.1097/BPO.0000000000002466.
[31]	Wu L, Wei S W, Chen Z, et al. Ultrasound-guided paravertebral block with liposomal bupivacaine vs. non-liposomal bupivacaine for postoperative pain control after the Nuss procedure in children:a randomized clinical trial[J]. J Clin Anesth, 2025, 106:111953. doi:10.1016/j.jclinane.2025.111953.
[32]	Wan M, Liang X, Meng J, et al. Clinical effectiveness of perineural liposomal bupivacaine is not superior to bupivacaine hydrochloride for the prevention of postoperative pain in orthopedic surgery:a systematic review and meta-analysis with trial sequential analysis[J]. J Pain Res, 2025, 18:3627-3642. doi:10.2147/JPR.S525231.

布比卡因脂质体的药理特性与研究进展

The pharmacological properties and research status of liposomal bupivacaine

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 32

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郑宏茹, 王志芬, 李明珊, 王昊琦, 元新颖, 杜琳娜, 刘金柱. 2种术前镇静用药对小儿全凭静脉麻醉术中qCON和qNOX及维持用药的影响[J]. 天津医药, 2026, 54(8): 865-869.
[2]	胡小彤, 王蕾, 杨涛. GMA郁金香喉罩与气管插管在机器人辅助腹腔镜直肠切除术中的应用对比[J]. 天津医药, 2026, 54(6): 632-636.
[3]	吕路, 朱杰昌, 王峥, 秘家学. 超声引导下股鞘内浸润麻醉在腹主动脉瘤腔内修复术中的应用[J]. 天津医药, 2026, 54(6): 643-646.
[4]	段程丽, 申彦杰, 郭丽霞, 王碧航, 俎晓霞, 刘玉强. 硬膜外镇痛产妇产时发热时刻和发热峰值对新生儿不良结局的交互作用分析[J]. 天津医药, 2026, 54(4): 364-368.
[5]	赵丽, 马秀丽, 刘毅, 朱毅. 全麻下腹腔镜胃癌根治术后谵妄发生的危险因素分析[J]. 天津医药, 2026, 54(3): 259-264.
[6]	熊炳贤, 王景坤, 刘衬云, 陈惠群. 不同浓度罗哌卡因竖脊肌平面阻滞对胸腔镜肺叶切除术患者的影响[J]. 天津医药, 2026, 54(3): 314-318.
[7]	李丽, 王昊琦, 杨洋, 赵绪稳, 刘金柱. 七氟烷吸入复合骶管阻滞麻醉用于超低出生体重儿小肠坏死切除术多学科诊疗1例[J]. 天津医药, 2026, 54(2): 216-219.
[8]	郭青玉, 储成志. 威灵仙总皂苷调控miR-26a-5p/Wnt5a信号通路对三叉神经痛大鼠的镇痛作用[J]. 天津医药, 2025, 53(8): 802-807.
[9]	陈文婷, 陈国庆. 硬膜外分娩镇痛产时发热程度对母儿围生结局的影响[J]. 天津医药, 2025, 53(5): 474-477.
[10]	高岩, 马伟, 张瑜, 李蕾. 艾司氯胺酮对小儿四肢骨折术后辅助镇痛效果及预测模型构建[J]. 天津医药, 2025, 53(5): 483-487.
[11]	丁明, 戎国祥, 潘忠军. 自主呼吸非气管插管硬膜外麻醉下单孔胸腔镜手术治疗非小细胞肺癌的疗效分析[J]. 天津医药, 2025, 53(4): 411-415.
[12]	葛倩倩, 周圆圆, 徐翠琴, 许春梅, 胡树罡. 局部振动治疗对痉挛型偏瘫脑性瘫痪儿童上肢精细运动功能及表面肌电特征的影响[J]. 天津医药, 2025, 53(12): 1315-1319.
[13]	刘丹, 万南生, 王杰, 李广生, 谢巍, 田羽, 冯靖. 新型肺隔离穿刺消融术应用[J]. 天津医药, 2024, 52(9): 982-984.
[14]	朱文智, 邱倩, 谭宏宇. 术前焦虑对肝癌患者麻醉苏醒与术后恢复的影响[J]. 天津医药, 2024, 52(7): 762-765.
[15]	蒋玲玲, 李云, 盛奎, 张丽丽, 胡阳, 张野. 外侧弓状韧带上腰方肌与腹横肌平面阻滞对腹腔镜肝脏部分切除术后镇痛效果的研究[J]. 天津医药, 2024, 52(3): 302-305.